Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...
Donanemab trial patient: ‘I feel as normal as a 78-year-old can be’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-Effective
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
MedPage Today on MSN7d
Brain Edema Risk May Be Lower With Modified Donanemab Dosing
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An alternate dosing plan for the anti-amyloid ...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
STAT13d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
News Medical on MSN10d
MHRA greenlights donanemab for early stage Alzheimer’s disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
BMJ13d
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...
Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why
The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.
National Institute for Health and Care Excellence13d
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
Alzheimer's Society13d
Alzheimer's Society responds to MHRA and NICE announcements on donanemab
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...